Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020)
Retrieved on:
Tuesday, August 25, 2020
Lemborexant acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythms.
Key Points:
- Lemborexant acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythms.
- Lemborexant was approved in the U.S. for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, and was approved in Japan for the treatment of insomnia.
- The clinical development of lemborexant in patients with Irregular Sleep Wake Rhythm Disorder (ISWRD) associated with mild-to-moderate Alzheimer's dementia is ongoing.
- (3),(4) In particular, older adults tend to have a higher prevalence rate with many experiencing insomnia symptoms for months to years.